Claire Harrison, MD, deputy chief medical officer at the Guy’s and St. Thomas’ NHS Foundation in the United Kingdom, discusses results from the phase 1 trial of INCA033989 in CALR-mutant myelofibrosis, which were presented at the 2026 European Hematology Association Congress in Stockholm, Sweden.
The phase 1 trial data showed that INCA033989, a first-in-class mutant calreticulin(mutCALR)-targeted monoclonal antibody, delivered rapid and durable clinical benefits including meaningful spleen volume reductions and symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinib.
“This is a drug that was well-tolerated, 84% of patients remain on, we are seeing robust responses in our conventional measures of spleen and symptoms,” Dr. Harrison said. “We are also seeing clear evidence of disease modification.”
She also said that similar data was seen in essential thrombocytosis and that phase 3 studies will be forthcoming within the next six months.
Leave feedback about this